

NIH RELAIS Document Delivery

NIH-10094729

NIH -- W1 J0828H

JANICE LEE
NIDCR/NIH, bldg 30, rm 229
Bethesda, MD 20892

ATTN:	SUBMITTED:	2001-12-19 13:50:59
PHONE: 301-435-1674	PRINTED:	2001-12-20 12:55:36
FAX: -	REQUEST NO.:	NIH-10094729
E-MAIL:	SENT VIA:	LOAN DOC 5339232

NIH	Fiche to Paper	Journal
TITLE:	JOURNAL OF PEDIATRICS	
PUBLISHER/PLACE:	Mosby-Year Book St. Louis Mo	
VOLUME/ISSUE/PAGES:	1978 Feb;92(2):220-6	220-6
DATE:	1978	
AUTHOR OF ARTICLE:	Giovannelli G; Bernasconi S; Banchini G	
TITLE OF ARTICLE:	McCune-Albright syndrome in a male child: a clinic	
ISSN:	0022-3476	
OTHER NOS/LETTERS:	Library reports holding volume or year 0375410 340627	
SOURCE:	PubMed	
CALL NUMBER:	W1 J0828H	
NOTES:	i do not have an ip address at this terminal.	
REQUESTER INFO:	JANICELEE	
DELIVERY:	E-mail: jlee@dir.nidcr.nih.gov	
REPLY:	Mail:	

NOTICE: THIS MATERIAL MAY BE PROTECTED BY COPYRIGHT LAW (TITLE 17, U.S. CODE)

-----National-Institutes-of-Health,-Bethesda,-MD-----

McCune-Albright syndrome in a male child: A clinical and endocrinologic enigma

A 6½-year-old boy with polyostotic fibrous dysplasia, café-au-lait pigmentation of the skin, and precocious pubertal development was studied for two years. Parathormone, calcium, phosphorus, testosterone, cortisol, and growth hormone levels were within normal limits. Urinary 17-ketosteroids, 17-ketogenic steroids, and estrogens were at the upper limits of normal. After GnRH stimulation, there was only a very slight increase in LH and no increase in FSH. There was no increase in TSH after TRH, and plasma levels of T_4 and T_3 were normal. The plasma prolactin level was within normal limits, and increased after TRH stimulation (with a second, delayed upsurge). Abnormal distribution of ^{131}I in the thyroid was evident, without clearcut evidence of hyperfunctioning areas after TSH stimulation and T_3 suppression tests followed by conventional scanning and gamma camera scintiphotography. Our findings do not support the claimed, single, hypothalamic origin of the disease that is presumed to result in overproduction of releasing hormones; they are more in keeping with a pleiotropic, scattered peripheral lesion, possibly of embryonal origin.

Giorgio Giovannelli, M.D.,* Sergio Bernasconi, M.D., and
Giacomo Banchini, M.D., Parma, Italy

THE ASSOCIATION of polyostotic fibrous dysplasia, café-au-lait pigmentation of the skin, and development of precocious puberty, first mentioned by Weil in 1922,¹ is known as the McCune-Albright syndrome. Since the etiology and pathogenesis of the disorder are still unknown, we report here studies of a 6½-year-old boy. The syndrome occurs predominantly in girls; only ten boys have been reported with precocious puberty.² The puberty which occurs in this condition has been referred to as both "true" and "pseudo" precocious puberty by different authors,^{13, 16} depending upon the endocrinologic and histologic findings observed in individual cases. As for the pathogenesis, the long-held hypothesis that there is a single, central origin, because of overproduction of hypothalamic-releasing hormones³ is now in question. More recent evidence suggests that the disorder is of

multiple, peripheral origin and that there is autonomous hyperfunctioning of target glands.⁴

There is a well-known association between sexual precocity and other endocrinopathies,³ particularly adenomatous hyperthyroidism,^{5, 10, 13} Cushing disease,^{11, 12} and acromegaly.¹⁴

Abbreviations used

hCG:	human chorion gonadotropin
GH:	growth hormone
GnRH:	gonadotropin-releasing hormone
FSH:	follicle-stimulating hormone
LH:	luteinizing hormone
TRH:	thyroid-releasing hormone
PRL:	prolactin
RIA:	radioimmunoassay
T_3 :	tri-iodothyronine
T_4 :	thyroxine

CASE REPORT

Patient B. P., a 6½-year-old boy, was referred to the pediatric department because of a hard, painless swelling on the upper, medial aspect of the right maxilla. He was the youngest child of a 43-year-old mother who had had four pregnancies. A term male

From the Department of Pediatrics, University of Parma.

Presented in part at the Fourteenth Annual Meeting of the European Society for Pediatric Endocrinology, Berlin, September, 1975.

*Reprint address: Istituto di Clinica Pediatrica, Ospedale Maggiore, 43100 Parma, Italy.




Fig. 1. The patient on admission (6 $\frac{5}{12}$ years).

infant was born of her first pregnancy; he is now 14 years old and in good health; the second and third pregnancies ended in spontaneous abortions three months (retroversion of the uterus); the fourth pregnancy was term, but there was threatened abortion at 6 $\frac{1}{2}$ months. The father, a 52-year-old man, had had a right orchiectomy at age 48 for seminoma, that had appeared six years after orchiopexy for cryptorchidism.

The infant weighed 3,800 gm at birth and growth and psychomotor development were normal. When he was one year of age his mother noticed enlargement of both testes, the left being more prominent. Enlargement progressed slowly until age

Table I. Auxologic data and in vitro thyroid function tests

Data	Initial and follow-up observations			
	Admission	Second	Third	Fourth
Age (yr)	6 $\frac{5}{12}$	6 $\frac{8}{12}$	7 $\frac{2}{12}$	8 $\frac{8}{12}$
Bone age (yr)*	6	7	8	11
Height (cm)	123.2	126.4	130.8	143
Percentile†	90	90-97	90-97	97
Height-velocity (cm/yr)		10.7		7.9
Testicles (cm ³)‡	r = 6 l = 10-12	r = 10-12 l = 15	r = 10-12 l = 15	r = 12 l = 15
Penis-length (cm)	6	6	6	7.5
Pubic hair	P ₁	P ₁	P ₁ -P ₂	P ₂ -P ₃
T ₃ (RIA) (ng/dl)	—	202	204	—
T ₄ (RIA) (μg/dl)	—	7.2	—	—
T ₄ (D) (μg/dl)	9.2	—	7.9	—
LATS	—	Negative	Negative	—
Antithyroglobulin antibodies	—	—	Negative (TRC)	Negative (RIA)

*According to Greulich and Pyle.

†According to Tanner.

‡Orchidometer of Prader.

4 and more rapidly thereafter. The enlargement was always more pronounced on the left side (the mother has been carefully observing the testes because of her husband's previous orchiectomy). A hydrocele was treated with an unknown local method without benefit by the family physician. At age 6, the child developed a painful limp, and after a few months he was referred to us.

The following clinical, growth, and laboratory findings have been gathered in four periods during a period of two years. His general appearance is shown in Fig. 1 (the pigmentation was present at birth, darkened over the next two weeks, then remained unchanged). Growth data are presented in the first column of Table I. Radiologic investigation revealed sclerosis of the base of the skull and of periorbital and facial bones; areas of fibrous dysplasia were scattered throughout the body with rather symmetric distribution; there was widespread but not generalized osteoporosis of variable degree. Growth and sexual development on admission (Table I) showed some contrasting features. The left testis was already adult in size, but the penis was infantile; pubic hair was absent. There was no advancement of bone age.

Biopsy of the left testis revealed large tubular diameters (90 to 170 μ), and scattered areas where all stages of spermatogenesis were visible (Fig. 2); Leydig cells were rare.

At follow-up examination, there was rapid advancement of bone age, presence of a growth spurt, and an increase in the size of both testes. The size of the penis remained unchanged, but a small tuft of straight, thin, slightly pigmented hair was visible at the left base of the penis the time of the third observation (Table




Fig. 2. Mature tubules with evidence of all stages of spermatogenesis.

I). Increased length of the penis was first noticed at the fourth visit.

The following studies were within normal limits: complete blood count, blood glucose and urea nitrogen, protein electrophoresis, serum calcium, phosphorus concentrations, urinalysis, urinary excretion of calcium, phosphorus and vanillylmandelic acid. The following were considered to be at the upper limits of normal: estrogens, 11 $\mu\text{g}/24$ hour (normal values for adult men, 10 to 25 $\mu\text{g}/24$ hour); 17-ketosteroids, 2.2 mg/24 hours (normal for the age, 0 to 2 mg/24 hours); 17-ketogenic steroids, 3.8 mg/24 hours (normal for the age, 0 to 4 mg/24 hours). Alkaline phosphatase level was slightly elevated for our laboratory standards (10 Bessey-Lowry units). Other endocrinologic investigations revealed the following results: normal parathormone, 8 ng/ml (normal, up to 40 ng/ml); plasma testosterone, before and after stimulation with hCG at high normal prepubertal levels (baseline level, 0.5 ng/ml; peak level after 4 days, 1.40 ng/ml); normal plasma cortisol level (20.8 $\mu\text{g}/\text{dl}$), with increase ($\Delta = 11.8$ $\mu\text{g}/\text{dl}$ after 60 minutes) after insulin stimulation and with normal circadian variations (18.2 to 9.3 $\mu\text{g}/\text{dl}$ at 8 AM and 4 PM, respectively); normal growth hormone secretion pattern after insulin (baseline level, 1 ng/ml; peak level, 17 ng/ml.)

The secretion of gonadotropins after GnRH stimulation, investigated three times, showed only a slight increase of LH, even under the normal range for prepubertal subjects (Fig. 3). No apparent increase of FSH was demonstrable on any occasion (Fig. 4).

After TRH stimulation test, performed on admission and during the second and fourth visits, there was no increase in the level of TSH or of T_4 or T_3 after 120 minutes (Fig. 5).

Plasma prolactin level rose normally after TRH stimulation (baseline level, 14 ng/ml; peak level, 25 ng/ml).

In vitro thyroid function tests were repeatedly normal (Table I). ^{131}I -uptake test was also normal; moreover, values showed a normal increase after TSH stimulation and a decrease after the T_4 suppression test (Fig. 6). Abnormal distribution of radioactive iodine in the gland was evident on color scanning; TSH stimulation test failed to reveal any dormant area in the right lobe or elsewhere; the incomplete suppression after T_4 directed our attention to the lower part of the left lobe. However, computer-assisted ^{99m}Tc -scintiphographic investigation, subsequently performed, showed no remarkable prevalence of radioactivity in the lower left lobe and proved more in keeping with a polycentric distribution.




Fig. 3. Luteinizing hormone (LH) area = normal; — = our patient; = normal.

METHODS

Human chorionic gonadotropin (hCG) was done with 5000 IU. The method of Ziegler and Rabinowitz¹² was used to determine by RIA both testosterone and LH. In our laboratory, the sensitivity was 0.24 ± 0.06 ng/ml and the specificity was 0.63 ± 0.14 ng/ml.

An insulin tolerance test was performed intravenously. Growth hormone was determined by a radioimmunoassay method.¹³ Gonadotropins were determined by a radioimmunoassay method using FSH and LH antibodies.

A similar method was used for TSH and TSH was determined by a radioimmunoassay method and in another laboratory (RIA) and T_4 (RIA).

Plasma Prolactin was determined by a double-antibody method.

DISCUSSION

The clinical picture revealed the skeletal lesions.




Fig. 3. Luteinizing hormone after intravenous GnRH. Shaded area = normal range for prepubertal children (N = 15); — = our patient on admission; ---- = second observation; = fourth observation (see Table I).

METHODS

Human chorionic gonadotropin stimulation test was done with 5,000 U/m² intramuscularly according to the method of Zachmann.¹⁷ Testosterone levels were determined by RIA using a CEA-SORIN kit. By this method both testosterone and dihydrotestosterone are measured. In our laboratory the normal baseline values are 0.24 ± 0.06 ng/ml ($\bar{x} \pm \text{SEM}$) in prepubertal children and 0.63 ± 0.14 ng/ml at early puberty (Tanner Stage 2).

An insulin tolerance test was performed with rapid intravenous injection of 0.1 U/kg of regular insulin. Growth hormone was assayed by the double-antibody method.¹⁸ GnRH and TRH tests were done by intravenous injection of 100 and 200 $\mu\text{g}/1.73 \text{ m}^2$, respectively. FSH and LH were determined by RIA with a double-antibody method¹⁹ using SERONO materials.

A similar method²⁰ with materials of SERONO was used for TSH determination. On one occasion LH, FSH, and TSH were tested simultaneously in our laboratory and in another; the results were almost identical. T₃ (RIA) and T₄ (RIA) were determined using LEPETIT materials.

Plasma PRL levels were determined by RIA using a double-antibody and filtration method (SERONO materials).

DISCUSSION

The clinical and laboratory studies in our patient revealed the following: (1) the presence of multiple skeletal lesions with no demonstrable impairment of




Fig. 4. Follicle-stimulating hormone after intravenous GnRH. Shaded area = normal range for prepubertal children (N = 15); — = our patient on admission; ---- = second observation; = fourth observation (see Table I).




Fig. 5. TSH after intravenous TRH; — = our patient on admission; ---- = second observation; = on fourth observation (see Table I). Shaded area = normal range in healthy children (N = 19).

parathyroid function; (2) lack of increase in levels of TSH, FSH, and LH after stimulation with the corresponding hypothalamic-releasing hormones; (3) premature sexual development, which corresponds neither with the pattern


¹³¹I-THYROID UPTAKE AND SCANNING

Fig. 6. In vivo thyroid function findings and related behavior after TSH stimulation and T₃ suppression tests.

expected with "true" hypothalamic, nor with "pseudo" precocious puberty. Spermatogenesis was present, even though levels of FSH were low in the basal state and did not increase after GnRH stimulation. Even though the testes were in the adult range of size, penile size was prepubertal, and there was absence of other secondary sexual characteristics and no advancement of bone age (on admission), and (4) abnormal shape of the thyroid gland, in the absence of clinical signs of dysfunction.

A likely explanation for the osseous abnormality is the presence of a congenital abnormal reactivity of clones of cells scattered in the skeletal tissue. The large "silent" area in the right lobe of the thyroid could be explained by a congenital anomaly, perhaps absence of tissue or presence of adenomatous tissue of embryonal type, incapable of

¹³¹I uptake. This appears more likely than suppression of thyroid tissue resulting from surrounding hyperfunctioning areas. Failure of increase of TSH after TRH could represent a very early sign of primary, but still subclinical, hyperthyroidism. The unresponsiveness of FSH and, to a lesser degree, of LH to GnRH stimulation could result from pituitary suppression by testicular substances, probably other than testosterone.²¹ On the other hand, primary pituitary involvement affecting the beta cells (their overwhelming number and marked pleomorphism having been well documented by Sternberg and Joseph⁶ at autopsy of a patient) could constitute an alternative and more encompassing explanation of the observed behavior of the three hormones after stimulation with the corresponding releasing factors.

Although how or when puberty begins is not clear, it is known that the pituitary gonadotropins, LH and FSH, are essential to the development of the reproductive system. Our observations on the hypothalamic-pituitary axis in our patient suggest that the central nervous system involvement in the clinical picture is not limited to the

CONCLUSION

In spite of the absence of endocrine abnormalities, the syndrome of scattered bone metastases (skeletal metastases) is one to be described as a form of congenital abnormality.

Recent studies on the ectodermal layer through the mucosa, in the neuroectodermal layer, in the medulla, in the parathyroid gland, and in the body of the thyroid gland.

A congenital abnormality, tentatively named "congenital multiple endocrine syndrome," is a remarkable syndrome described by DiGeorge.

The abnormality is not rare. Boenheim and his colleagues have described fibrous dysplasia of the areas of development of the periosteum, which is never found in the bone; its cause is not clear. On the

Although we can draw no definite conclusion about how or where the primary stimulus of the precocious puberty has been triggered in this child, it does not appear that the process is sustained by hypersecretion of gonadotropins. Moreover, the lack of response of gonadotropins to the exogenous releasing hormones is not in keeping with the hypothesis of hypersecretion of hypothalamic-releasing hormones as the cause of the disease.

Our observations do not support the proposed single hypothalamic origin of the disease.³ A possible explanation in our patient could be primary involvement of some pituitary cell clumps (mainly the beta cells), probably in the context of pleiotropic glandular lesion (see thyroid involvement in our case), which could explain the variable clinical patterns described in this rare syndrome.

CONCLUSION

In spite of the well-known pleomorphism of the clinical and endocrinologic patterns in the McCune-Albright syndrome, the constant feature of the disorder is the scattering of involvement of affected body structures (skeleton, skin, and endocrine glands) which would lead one to hypothesize the presence of multiple, circumscribed embryonic alterations in a variety of tissues, in the form of clones of cells characterized by their aberrant behavior to otherwise normal stimuli.

Recently, the hypothesis has been put forward that the ectodermal and endodermal endocrine glands are related through a common stem cell present in the foregut mucosa, i.e., a multipotential endocrine cell probably of neuroectodermal origin.⁹ As is generally admitted, the ectodermal derivatives are the pituitary and adrenal medulla; the endodermal or foregut derivatives are the parathyroid, thyroid, pancreatic islets, and ultimobranchial body.

A congenital dysplasia of some of these stem cells could tentatively explain the origin of the McCune-Albright syndrome, and, as proposed by Weichert,⁹ the origin for multiple endocrine adenomatosis. In this connection the remarkable similarity of many aspects of these two syndromes has been discussed in a commentary by DiGeorge.⁷

The association of alterations of bone tissue (mesodermal derivative) with endocrine or neurologic diseases is not rare (this subject has been extensively reviewed by Boenheim and McGavack²²). Moreover, the polyostotic fibrous dysplasia is also a scattered lesion; the dysplastic areas develop inside the bone; the surrounding cortex and periosteum remain intact; the accompanying osteoporosis is never generalized and may be associated to osteosclerosis; its course is not progressive.²²

On the whole, our findings and present knowledge

seem to be more in keeping with a pleiotropic, scattered peripheral lesion, possibly of embryonal origin, in the McCune-Albright syndrome.

Although new knowledge has been gained, it still may be pertinent to quote from Albright's original paper, "It might be wiser only to describe the condition and not try to come to any conclusion concerning its etiology and the relation of one manifestation to another".⁸

We are grateful to Dr. J.A. Fischer (University of Zürich) for measuring parathormone, to Dr. A. Pinchera (University of Pisa) for determining LATS and antithyroglobulin antibodies, to Dr. Marta Rocca, physicist, for the statistical assessment of data, to Giuseppe Nori, for technical assistance, and to Piera Dallatoma-sina for secretarial work (Department of Pediatrics, University of Parma).

REFERENCES

1. Weil: Sitzung vom 14. Juli 1922 der medizinischen Sektion der Schlesischen Gesellschaft für vaterländische Kultur zu Breslau, *Klin Wochenschr* 42:2114, 1922.
2. Lightner ES, Penny R, and Frasier SD: Growth Hormone excess and sexual precocity in polyostotic fibrous dysplasia (McCune-Albright syndrome): Evidence for abnormal hypothalamic function, *J PEDIATR* 87:922, 1975.
3. Hall R, and Warrick C: Hypersecretion of hypothalamic releasing hormones: a possible explanation of the endocrine manifestations of polyostotic fibrous dysplasia (Albright's syndrome), *Lancet* 1:1313, 1972.
4. Danon M, and Crawford JD: Sexual precocity in polyostotic fibrous dysplasia: evidence for inclusion as another multiple endocrine adenomatosis syndrome, *Proc fourteenth International Congress of Pediatrics, Buenos Aires 1974*, vol 5, p 108.
5. Hamilton CR Jr, and Maloof F: Unusual types of hyperthyroidism, *Medicine* 52:195, 1973.
6. Sternberg WH, and Joseph V: Osteodystrophia fibrosa combined with precocious puberty and exophthalmic goiter (Pathologic report of a case), *Am J Dis Child* 63:748, 1942.
7. DiGeorge AM: Albright syndrome: Is it coming of age? *J PEDIATR* 87:1018, 1975.
8. Albright F, Butler AM, and Hampton AO: Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females: report of five cases. *N Engl J Med* 216:727, 1937.
9. Weichert RF III: The neural ectodermal origin of the peptidesecreting endocrine glands. A unifying concept for the etiology of multiple endocrine adenomatosis and the inappropriate secretion of peptide hormones by non-endocrine tumors, *Am J Med* 49:232, 1970.
10. Zangeneh F, Lulejian GA, and Steiner MM: McCune-Albright syndrome with hyperthyroidism, *Am J Dis Child* 111:644, 1966.
11. Aarskog D, and Tveteraas E: McCune-Albright's syndrome following adrenalectomy for Cushing's syndrome in infancy, *J PEDIATR* 73:89, 1968.
12. Danon M, Robboy SJ, Kim S, Scully R, and Crawford JD: Cushing syndrome, sexual precocity, and polyostotic fibrous

- dysplasia (Albright syndrome) in infancy, *J PEDIATR* 87:917, 1975.
13. Benedict PH: Endocrine features in Albright's syndrome (fibrous dysplasia of bone), *Metabolism* 11:30, 1962.
 14. Scurry MT, Bicknell JM, Fajans SS, and Arbor A: Polyostotic fibrous dysplasia and acromegaly, *Arch Intern Med* 114:40, 1964.
 15. Benedict PH: Sex precocity and polyostotic fibrous dysplasia. Report of a case in a boy with testicular biopsy, *Am J Dis Child* 111:426, 1966.
 16. Pray LG: Sexual precocity in females: report of two cases with arrest of precocity in the McCune-Albright syndrome after removal of a cystic ovary, *Pediatrics* 8:684, 1951.
 17. Zachmann M: The evaluation of testicular endocrine function before and in puberty, *Acta Endocrinol, Suppl* 164, 1972.
 18. Molinatti GM, Massara F, Strumia E, Pennisi F, Scassellati GA, and Vancheri L: Radioimmunoassay of human growth hormone, *J Nucl Biol Med* 26:13, 1969.
 19. Midgley AR Jr: Radioimmunoassay for human chorionic gonadotrophin and human luteinizing hormone, *Endocrinology* 79:10, 1966.
 20. Odell WD, and Rand HR: The radioimmunoassay of human thyrotrophin, *Br J Hosp Med* 2:1366, 1969.
 21. Short RV: Hormonal control of spermatogenesis, *Nature* 254:103, 1975.
 22. Boenheim F, and McGavack TH: Polyostotische fibröse Dysplasie, *Ergeb Inn Med Kinderheilkd* 3:157, 1952.

Information for authors

Most of the provisions of the Copyright Act of 1976 became effective on January 1, 1978. Therefore, all manuscripts must be accompanied by the following statement, signed by each author: "The undersigned author(s) transfers all copyright ownership of the manuscript entitled (title of article) to The C. V. Mosby Company in the event the work is published. The author(s) warrants that the article is original, is not under consideration by another journal, and has not been previously published." Authors will be consulted, when possible, regarding republication of their material.